---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-077821"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2023-07-05T23:59:59+00:00"
generated_at: "2026-06-13T12:37:28.119716+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Protagonist: Ph2 REVIVE hits primary endpoint (p=0.0003); Ph3 VERIFY enrollment completion expected 1Q 2024

## Summary
- Phase 2b FRONTIER 1 trial of JNJ-2113 in moderate-to-severe psoriasis completed; Phase 3 psoriasis study initiation planned.
- Enrollment completion for Phase 3 VERIFY trial of rusfertide in polycythemia vera expected in 1Q 2024.
- Phase 2 REVIVE study met primary endpoint with high statistical significance (p=0.0003); 69.2% responders vs 18.5% placebo.
- Rusfertide showed rapid hematocrit control in PACIFIC study; safety profile generally well tolerated with no new signals.
- New Phase 2b study of JNJ-2113 in ulcerative colitis planned for 4Q 2023; cash runway through end of 2025.

## SEC filing metadata
- accession: 0001104659-23-077821
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2023-07-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465923077821/0001104659-23-077821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465923077821/tm2320477d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-077821
- JSON: https://secwatch.observer/filing/0001104659-23-077821.json
- Plain text: https://secwatch.observer/filing/0001104659-23-077821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.